Table 4.

Collaborative wide population health registry baseline data^a

Total Patient Sample (n = 96,140)	N (%)
Demographic	Total
Gender
Female  Male  Unknown	48,424 (50.4%) 47,713 (49.6%) 3 (0.0%)
Age (years)
≥ 65  < 65	46,415 (48.3%) 49,725 (51.7%)
HbA1c b	N = 49,472
< 7%  7-7.9%  ≥ 8.0%	32,787 (66.3%) 9,292 (18.8%) 7,393 (14.9%)
BMI c	N = 59,445
≤ 24.99  25.0-29.99  ≥ 30.0	5,748 (9.7%) 15,181 (25.5%) 38,516 (64.8%)
Medications for glycemia and CGM d, e
Carve out or unknown	24,536 (25.5%)
No carve outd	71,604 (74.5%)
Medication utilizatione
GLP-1 receptor agonist	8,187 (11.4%)
SGLT2i inhibitor	5,828 (8.1%)
Insulin basal bolus (Short + Intermediate or Long-Acting Insulin)  Basal only (Intermediate or Long-Acting Insulin)	6,776 (9.5%) 6,575 (9.2%)
Metformin	29,826 (41.7%)
Sulfonylurea	9,082 (12.7%)
CGMf	1,542 (2.2%)

^aData was extracted from January 1, 2018 - January 1, 2022

^bDenominator of the percentages is the total participant sample who have HbA1c values (N = 49,472). Data Manipulation: HbA1c values less than 4.0% and greater than 20.0% were excluded from analyses

^cDenominator of the percentages is the total participant sample who have BMI values (N = 59,445). BMI values less than 15 and greater than 150 were excluded from analyses

^dSome groups/employers purchase separate pharmacy coverage through different vendors. This is called a “pharmacy carve out.” These vendors do not send claims data to MCT2D. Therefore, MCT2D is only able to provide pharmacy claims data on participants with BCBSM pharmacy coverage

^eMedications are displayed only for participants with no pharmacy carve out, total n = 71,604

^fContinuous glucose monitor (CGM) data is sourced from medical and pharmacy claims